DSIP

DSIP — delta sleep-inducing peptide — is a nine-amino-acid sequence isolated in 1977 by researchers in Switzerland. The experiment behind it was unusual: blood was taken from the cerebral circulation of rabbits in induced sleep, and a fraction of it was reported to produce slow-wave sleep when transferred to other animals. The peptide isolated from that fraction was named for what it appeared to do.

That experiment was testing a then-radical idea: that something circulating in the blood carries a sleep signal, rather than sleep being governed entirely by neural circuits. The principle was vindicated elsewhere — adenosine is now known to accumulate through waking and drive sleep pressure — which is what keeps the original question live.

What has never been identified is its receptor. For most peptides the receptor anchors the whole mechanistic account, so a nine-residue sequence with reported central activity and no known binding site is an anomaly worth investigating on its own terms — and it is why laboratories working on sleep signalling still order it half a century after its isolation.

• An unresolved question: Whether a circulating peptide can carry a sleep signal at all is a real question in sleep biology, and this compound is the original candidate for it.

• An unidentified binding site: Reported central activity with no receptor yet found is a genuine anomaly: either the receptor exists and has not been located, or the effects are indirect. Both are worth chasing, and both need the peptide itself.

• Reported beyond sleep: Published work describes effects on stress hormone release and pain thresholds as well. Whether that breadth indicates a general mechanism or inconsistent findings is itself the question.

• A precisely defined sequence: Whatever remains unsettled about its activity, the molecule itself is a fully characterised nine-residue peptide, which is what makes it usable as a fixed reference point in sleep and stress-signalling work.

Sleep is not one state. It cycles through stages, and deep slow-wave sleep is named for the large, slow electrical waves that appear across the cortex when huge numbers of neurons fire in synchrony. Those waves are what "delta" in the name refers to, and producing them was the original reported effect.

The idea being tested in the 1977 experiment was a humoral one: that something circulating in the blood carries a sleep signal, rather than sleep being governed entirely by neural circuits. That was a reasonable proposition, and the discovery of adenosine's role in sleep pressure later showed the general principle holds. Whether this particular peptide is such a signal is the part that was never settled.

Proposals in the literature include indirect effects on other neurotransmitter systems and on the release of hormones from the pituitary. These remain open lines rather than settled mechanism, which is why the peptide keeps appearing in work on how a sleep signal could be carried in the blood at all — a question the field has not closed.

Melatonin is the instructive comparison: a molecule with a mapped synthesis pathway, identified receptors, a measured phase response curve in humans and decades of replication. Both are described as sleep compounds and the evidence behind them is not remotely comparable.

Selank and Semax come from a research tradition with the same pattern of early promising reports and limited independent replication, though both have considerably more behind them than this.